Relief rally unfolding, here’s what to watch

I’m seeing real breakout potential

January 22, 2026

Issuer-Sponsored Content from Apimeds Pharmaceuticals, Inc*

Markets are rallying as new tariffs fears fade. Now the real setups are forming. One stock on my watchlist has built a convincing base, just popped on volume, and is now pressing up against a key decision level. Here’s what I’m focused on…

TODAY’S TOP ALERT! 

Apimeds Pharma (NYSE: APUS)

👉  APUS is TODAY’S #1 ALERT 👈

Good morning, Folks,

Stocks enjoyed a nice jump yesterday and were solidly green in the pre-market after President Trump called off his new Europe tariffs thanks to a “framework of a future deal with respect to Greenland.”

His earlier threats had roiled the markets, so this is much-welcomed relief.

For traders, the brief downturn helped reveal stocks that have true momentum. Now that market tailwinds are back, these are the tickers worth focusing on.

💥At the top of my watchlist today is Apimeds Pharmaceuticals US (APUS)*.

On December 1, the clinical-stage biopharma company added a big crypto angle to its story (details below) that resulted in mixed reactions from investors…

The stock traded sideways for a few weeks before dropping in mid-December and consolidating in the $1.50–$1.85 zone, where it stopped making lower lows.

Since late December, APUS has chopped with relatively low volatility, establishing a base.

After a 7.74% jump with volume yesterday, the stock is pushing against resistance around $1.80–$1.90…

If it holds above $1.75 and breaks above $1.90 with volume, that would signal a range breakout, and I would watch for a move toward its prior consolidation around $2.20–$2.30…

Right now, this chart is not about “catching a falling knife” and is showing clear upside if it can break out of this range.

With market momentum back in action, I’m watching APUS closely today for a potential gap up.

👉  APUS is TODAY’S #1 ALERT* 👈

The company itself has an interesting profile…

It was established in May 2020 as a subsidiary of Inscobee Inc., and IPO’d in May of last year.

Its primary asset is Apitox, which it licensed from Apimex Korea.

Apitox is a “purified, pharmaceutical-grade honeybee venom-based toxin administered intradermally” that “has been sold and used in South Korea since 2003.”

The company’s initial clinical focus has been on using Apitox to reduce pain and improve function in patients with knee osteoarthritis — a large, underserved market where many patients fail to get relief from injections, NSAIDs, or physical therapy.

The company has already completed a US Phase 3 trial for that indication where ~330 patients were treated, demonstrating clinical efficacy and safety.

Afterward, the FDA said APUS must conduct a separate, Phase 3b trial for patients with more severe, presurgical knee osteoarthritis.

Last July, the company said the study was “to be completed in ~24 months” and said its cash on hand was “sufficient to fund Apimeds through the completion of the trial.”

That’s great news for investors concerned about dilution risk.

Separately, the company holds rights to an FDA-cleared IND for a Phase 3 study in multiple sclerosis (MS) pain, an indication for which Apitox already has early anecdotal data. 

It envisions a single-site study with 25-35 patients for this “unmet need with no approved therapies.”

A major de-risking factor is that Apitox was “approved by the Korean Ministry of Food and Drug Safety in 2003 for the treatment of pain and inflammation associated with osteoarthritis.”

It says “>810,000 doses [have been] administered to patients at >1200 facilities, with no serious adverse events reported.”

I mentioned that on December 1, APUS added a crypto angle to its story…

The announcement was of a merger with MindWave Innovations Inc. — “a leading provider of institutional Digital Asset Treasury (DAT) solutions.”

The deal “pav[ed] the way for a dual-growth enterprise spanning advanced biotechnology and institutional digital-asset treasury solutions.”

MindWave has a “three-pronged strategic framework” that includes:

  1. Secure Digital Treasury Wallets for Corporations,

  2. AI-Enhanced Bitcoin Yield Generation, and

  3. A Validator-Powered Ecosystem supported by the $NILA Token.

APUS CEO Erik Emerson explained the logic behind the merger: “Biotech requires significant capital, and integrating a high-yield digital asset business with strong cash-flow potential will allow us to accelerate our therapeutic programs.”

The deal was supported by “a simultaneous PIPE of up to $100 million to advance Apimeds’ clinical programs and expand MindWave’s digital asset infrastructure.” [emphasis added]

That PIPE closed on December 10. APUS said it “reinforces the Company’s financial position and propels its late-stage non-opioid therapeutic programs toward key clinical and regulatory milestones.”

The financing also enabled “approximately 1,000 Bitcoin previously held by MindWave [to be] transferred into a segregated, risk-managed structure.”

For perspective, that 1,000 Bitcoin is worth approximately $90 million at today’s prices.

That crypto holding “is governed under a defined investment policy intended to preserve capital while generating programmatic returns that complement Apimeds’ traditional funding sources.” [emphasis added]

As you do your own research on APUS, be sure to review this very helpful July 2025 investor presentation, the press release about the MindWave merger, and the websites for Apimed and MindWave.

As always, be sure to approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of our compensation and other conflicts of interest, as well as additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: APUS has chopped in a defined band since late December, and after its 7.74% gain yesterday, it’s now flirting with resistance. With market tailwinds back in action, I’m watching it closely today to see if we get a range breakout form here.

💥Keep APUS at the top of your watchlist to see if we get the breakout!

To Your Success,

Jeff Bishop

P.S. Make sure you join me and hundreds of other traders in the Market Master’s trading room today for live trading signals and education. You can access it at no cost right now. 

*ISSUER-SPONSORED DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received twenty seven thousand five hundred dollars (cash) from Apimeds Pharmaceuticals, Inc (via Primetime Profiles) for a one day marketing program starting on January 22, 2026.

It might seem obvious, but while our client claims not to own any shares in Apimeds Pharmaceuticals, Inc, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into Apimeds Pharmaceuticals, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a securities broker-dealer, broker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulatory authority, or any self-regu1atory organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.